PMC:7102556 / 11874-12619 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"230","span":{"begin":582,"end":587},"obj":"Species"},{"id":"231","span":{"begin":81,"end":95},"obj":"Disease"}],"attributes":[{"id":"A230","pred":"tao:has_database_id","subj":"230","obj":"Tax:9606"},{"id":"A231","pred":"tao:has_database_id","subj":"231","obj":"MESH:D018352"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"However, several bottlenecks typically delay the approval of vaccines to prevent CoVs infection. First, a lack of proper animal models for evaluating vaccine efficacy. Second, there are limitations from the S protein itself, such as mutations in the neutralization antibody epitopes in S protein that can cause virus escape [45], or non-neutralization antibody epitopes in vaccines that may elicit antibody-mediated disease enhancement (ADE) [46]. Third, DNA vaccines may recombine with other viruses. Fourth, pre-existing immunity may eliminate the vaccine by removing the general human virus vectors [47]. Finally, there is the problem of return on investment which may be slow and, hence, inhibit investments and slow down the clinical study."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T67","span":{"begin":209,"end":216},"obj":"Body_part"},{"id":"T68","span":{"begin":265,"end":273},"obj":"Body_part"},{"id":"T69","span":{"begin":288,"end":295},"obj":"Body_part"},{"id":"T70","span":{"begin":352,"end":360},"obj":"Body_part"},{"id":"T71","span":{"begin":398,"end":406},"obj":"Body_part"},{"id":"T72","span":{"begin":455,"end":458},"obj":"Body_part"}],"attributes":[{"id":"A67","pred":"fma_id","subj":"T67","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A68","pred":"fma_id","subj":"T68","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A69","pred":"fma_id","subj":"T69","obj":"http://purl.org/sig/ont/fma/fma67257"},{"id":"A70","pred":"fma_id","subj":"T70","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A71","pred":"fma_id","subj":"T71","obj":"http://purl.org/sig/ont/fma/fma62871"},{"id":"A72","pred":"fma_id","subj":"T72","obj":"http://purl.org/sig/ont/fma/fma74412"}],"text":"However, several bottlenecks typically delay the approval of vaccines to prevent CoVs infection. First, a lack of proper animal models for evaluating vaccine efficacy. Second, there are limitations from the S protein itself, such as mutations in the neutralization antibody epitopes in S protein that can cause virus escape [45], or non-neutralization antibody epitopes in vaccines that may elicit antibody-mediated disease enhancement (ADE) [46]. Third, DNA vaccines may recombine with other viruses. Fourth, pre-existing immunity may eliminate the vaccine by removing the general human virus vectors [47]. Finally, there is the problem of return on investment which may be slow and, hence, inhibit investments and slow down the clinical study."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T42","span":{"begin":86,"end":95},"obj":"Disease"},{"id":"T43","span":{"begin":437,"end":440},"obj":"Disease"}],"attributes":[{"id":"A42","pred":"mondo_id","subj":"T42","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A43","pred":"mondo_id","subj":"T43","obj":"http://purl.obolibrary.org/obo/MONDO_0019383"}],"text":"However, several bottlenecks typically delay the approval of vaccines to prevent CoVs infection. First, a lack of proper animal models for evaluating vaccine efficacy. Second, there are limitations from the S protein itself, such as mutations in the neutralization antibody epitopes in S protein that can cause virus escape [45], or non-neutralization antibody epitopes in vaccines that may elicit antibody-mediated disease enhancement (ADE) [46]. Third, DNA vaccines may recombine with other viruses. Fourth, pre-existing immunity may eliminate the vaccine by removing the general human virus vectors [47]. Finally, there is the problem of return on investment which may be slow and, hence, inhibit investments and slow down the clinical study."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T131","span":{"begin":104,"end":105},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T132","span":{"begin":121,"end":127},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_33208"},{"id":"T133","span":{"begin":311,"end":316},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T134","span":{"begin":325,"end":327},"obj":"http://purl.obolibrary.org/obo/CLO_0053799"},{"id":"T135","span":{"begin":493,"end":500},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"},{"id":"T136","span":{"begin":582,"end":587},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_9606"},{"id":"T137","span":{"begin":588,"end":593},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"}],"text":"However, several bottlenecks typically delay the approval of vaccines to prevent CoVs infection. First, a lack of proper animal models for evaluating vaccine efficacy. Second, there are limitations from the S protein itself, such as mutations in the neutralization antibody epitopes in S protein that can cause virus escape [45], or non-neutralization antibody epitopes in vaccines that may elicit antibody-mediated disease enhancement (ADE) [46]. Third, DNA vaccines may recombine with other viruses. Fourth, pre-existing immunity may eliminate the vaccine by removing the general human virus vectors [47]. Finally, there is the problem of return on investment which may be slow and, hence, inhibit investments and slow down the clinical study."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T70","span":{"begin":209,"end":216},"obj":"Chemical"},{"id":"T71","span":{"begin":288,"end":295},"obj":"Chemical"},{"id":"T72","span":{"begin":455,"end":458},"obj":"Chemical"}],"attributes":[{"id":"A70","pred":"chebi_id","subj":"T70","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A71","pred":"chebi_id","subj":"T71","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"},{"id":"A72","pred":"chebi_id","subj":"T72","obj":"http://purl.obolibrary.org/obo/CHEBI_16991"}],"text":"However, several bottlenecks typically delay the approval of vaccines to prevent CoVs infection. First, a lack of proper animal models for evaluating vaccine efficacy. Second, there are limitations from the S protein itself, such as mutations in the neutralization antibody epitopes in S protein that can cause virus escape [45], or non-neutralization antibody epitopes in vaccines that may elicit antibody-mediated disease enhancement (ADE) [46]. Third, DNA vaccines may recombine with other viruses. Fourth, pre-existing immunity may eliminate the vaccine by removing the general human virus vectors [47]. Finally, there is the problem of return on investment which may be slow and, hence, inhibit investments and slow down the clinical study."}

{"project":"LitCovid-sentences","denotations":[{"id":"T75","span":{"begin":0,"end":96},"obj":"Sentence"},{"id":"T76","span":{"begin":97,"end":167},"obj":"Sentence"},{"id":"T77","span":{"begin":168,"end":447},"obj":"Sentence"},{"id":"T78","span":{"begin":448,"end":501},"obj":"Sentence"},{"id":"T79","span":{"begin":502,"end":607},"obj":"Sentence"},{"id":"T80","span":{"begin":608,"end":745},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"However, several bottlenecks typically delay the approval of vaccines to prevent CoVs infection. First, a lack of proper animal models for evaluating vaccine efficacy. Second, there are limitations from the S protein itself, such as mutations in the neutralization antibody epitopes in S protein that can cause virus escape [45], or non-neutralization antibody epitopes in vaccines that may elicit antibody-mediated disease enhancement (ADE) [46]. Third, DNA vaccines may recombine with other viruses. Fourth, pre-existing immunity may eliminate the vaccine by removing the general human virus vectors [47]. Finally, there is the problem of return on investment which may be slow and, hence, inhibit investments and slow down the clinical study."}

{"project":"2_test","denotations":[{"id":"32017984-29514901-69697755","span":{"begin":325,"end":327},"obj":"29514901"},{"id":"32017984-8236772-69697756","span":{"begin":443,"end":445},"obj":"8236772"},{"id":"32017984-31193016-69697757","span":{"begin":603,"end":605},"obj":"31193016"}],"text":"However, several bottlenecks typically delay the approval of vaccines to prevent CoVs infection. First, a lack of proper animal models for evaluating vaccine efficacy. Second, there are limitations from the S protein itself, such as mutations in the neutralization antibody epitopes in S protein that can cause virus escape [45], or non-neutralization antibody epitopes in vaccines that may elicit antibody-mediated disease enhancement (ADE) [46]. Third, DNA vaccines may recombine with other viruses. Fourth, pre-existing immunity may eliminate the vaccine by removing the general human virus vectors [47]. Finally, there is the problem of return on investment which may be slow and, hence, inhibit investments and slow down the clinical study."}